Literature DB >> 15661684

Cancer statistics, 2005.

Ahmedin Jemal1, Taylor Murray, Elizabeth Ward, Alicia Samuels, Ram C Tiwari, Asma Ghafoor, Eric J Feuer, Michael J Thun.   

Abstract

Each year, the American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute and mortality data from the National Center for Health Statistics. Incidence and death rates are age-standardized to the 2000 US standard million population. A total of 1,372,910 new cancer cases and 570,280 deaths are expected in the United States in 2005. When deaths are aggregated by age, cancer has surpassed heart disease as the leading cause of death for persons younger than 85 since 1999. When adjusted to delayed reporting, cancer incidence rates stabilized in men from 1995 through 2001 but continued to increase by 0.3% per year from 1987 through 2001 in women. The death rate from all cancers combined has decreased by 1.5% per year since 1993 among men and by 0.8% per year since 1992 among women. The mortality rate has also continued to decrease from the three most common cancer sites in men (lung and bronchus, colon and rectum, and prostate) and from breast and colorectal cancers in women. Lung cancer mortality among women has leveled off after increasing for many decades. In analyses by race and ethnicity, African American men and women have 40% and 20% higher death rates from all cancers combined than White men and women, respectively. Cancer incidence and death rates are lower in other racial and ethnic groups than in Whites and African Americans for all sites combined and for the four major cancer sites. However, these groups generally have higher rates for stomach, liver, and cervical cancers than Whites. Furthermore, minority populations are more likely to be diagnosed with advanced stage disease than are Whites. Progress in reducing the burden of suffering and death from cancer can be accelerated by applying existing cancer control knowledge across all segments of the population.

Entities:  

Mesh:

Year:  2005        PMID: 15661684     DOI: 10.3322/canjclin.55.1.10

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  1240 in total

1.  Programmed cell death 6 (PDCD6) as a prognostic marker for gastric cancers.

Authors:  Jung Hwan Yoon; Yoo Jin Choi; Sung Geun Kim; Suk Woo Nam; Jung Young Lee; Won Sang Park
Journal:  Tumour Biol       Date:  2011-12-13

Review 2.  "Vanishing liver metastases"-A real challenge for liver surgeons.

Authors:  Alex Zendel; Eylon Lahat; Yael Dreznik; Barak Bar Zakai; Rony Eshkenazy; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

3.  Expression of CXCR-4 and IDO in human colorectal cancer: An immunohistochemical approach.

Authors:  Masaichi Ogawa; Michiaki Watanabe; Takuo Hasegawa; Kohei Ichihara; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  Mol Clin Oncol       Date:  2017-04-04

4.  Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis.

Authors:  Jingxun Wu; Xuan Wu; Wenhua Liang; Chunling Chen; Lingling Zheng; Hanxiang An
Journal:  Tumour Biol       Date:  2013-12-11

5.  Disseminating end-of-life education to cancer centers: overview of program and of evaluation.

Authors:  Marcia Grant; Jo Hanson; Patricia Mullan; Maren Spolum; Betty Ferrell
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

6.  Shopping for nutrition-based complementary and alternative medicine on the Internet: how much money might cancer patients be spending online?

Authors:  Mohammad Anas Alsawaf; Aminah Jatoi
Journal:  J Cancer Educ       Date:  2007       Impact factor: 2.037

7.  Identification of proteomic differences between squamous cell carcinoma of the lung and bronchial epithelium.

Authors:  Gereon Poschmann; Barbara Sitek; Bence Sipos; Anna Ulrich; Sebastian Wiese; Christian Stephan; Bettina Warscheid; Günter Klöppel; Ann Vander Borght; Frans C S Ramaekers; Helmut E Meyer; Kai Stühler
Journal:  Mol Cell Proteomics       Date:  2009-01-27       Impact factor: 5.911

8.  The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate.

Authors:  Ravi P Sahu; Sanjay K Srivastava
Journal:  J Natl Cancer Inst       Date:  2009-01-27       Impact factor: 13.506

9.  Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.

Authors:  Eiji Kikuchi; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Shuji Mikami; Yair Lotan; Mesut Remzi; Christian Bolenz; Cord Langner; Alon Weizer; Francesco Montorsi; Karim Bensalah; Theresa M Koppie; Mario I Fernández; Jay D Raman; Wassim Kassouf; Christopher G Wood; Nazareno Suardi; Mototsugu Oya; Shahrokh F Shariat
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

10.  TNM staging with FDG-PET/CT in patients with primary head and neck cancer.

Authors:  Patrick Veit-Haibach; Christopher Luczak; Isabel Wanke; Markus Fischer; Thomas Egelhof; Thomas Beyer; Gerlinde Dahmen; Andreas Bockisch; Sandra Rosenbaum; Gerald Antoch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.